Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease.

Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease.
复制标题

DOI:
10.1186/s12974-023-02965-w
复制
发表时间:
2023-11-30
影响因子:
9.3
通讯作者:
--
中科院分区:
医学1区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

颗粒蛋白前体(PGRN)表达的改变与多种神经退行性疾病(ND)相关,包括额颞叶痴呆(FTD)、阿尔茨海默病(AD)、帕金森病(PD)和溶酶体贮积症(LSD)。最近,PGRN的丧失显示导致内-溶酶体系统功能障碍和与ND相关的另一种蛋白质,糖蛋白非转移性B(GPNMB)的表达的年龄依赖性增加。目前尚不清楚GPNMB在PGRN不足的背景下发挥什么作用,以及它们如何相互作用并促进ND的发展或进展。本文综述了这两个关键蛋白质之间的相互作用的背景下,内溶酶体的健康,免疫功能和炎症,在其贡献ND。PGRN和GPNMB是调节疾病相关过程的相互关联的蛋白质,并且可能具有作为治疗靶点以延迟疾病进展或延长治疗窗的价值。
Alterations in progranulin (PGRN) expression are associated with multiple neurodegenerative diseases (NDs), including frontotemporal dementia (FTD), Alzheimer’s disease (AD), Parkinson’s disease (PD), and lysosomal storage disorders (LSDs). Recently, the loss of PGRN was shown to result in endo-lysosomal system dysfunction and an age-dependent increase in the expression of another protein associated with NDs, glycoprotein non-metastatic B (GPNMB). It is unclear what role GPNMB plays in the context of PGRN insufficiency and how they interact and contribute to the development or progression of NDs. This review focuses on the interplay between these two critical proteins within the context of endo-lysosomal health, immune function, and inflammation in their contribution to NDs. PGRN and GPNMB are interrelated proteins that regulate disease-relevant processes and may have value as therapeutic targets to delay disease progression or extend therapeutic windows.
DOI: 10.1186/s12974-021-02203-1
发表时间: 2021-07-25
影响因子: 9.3
作者:
Takahashi K;Nakamura S;Otsu W;Shimazawa M;Hara H
通讯作者: Hara H
DOI: 10.1016/j.neurobiolaging.2016.02.019
发表时间: 2016-05-01
影响因子: 4.2
作者:
Almeida, Maria R.;Macario, Maria C.;Santana, Isabel
通讯作者: Santana, Isabel
DOI: 10.1016/j.neurobiolaging.2006.10.028
发表时间: 2008-03-01
影响因子: 4.2
作者:
Benussi, Luisa;Binetti, Giuliano;Ghidoni, Roberta
通讯作者: Ghidoni, Roberta
DOI: 10.1186/s13024-018-0288-y
发表时间: 2018-10-16
影响因子: 15.1
作者:
Beel S;Herdewyn S;Fazal R;De Decker M;Moisse M;Robberecht W;Van Den Bosch L;Van Damme P
通讯作者: Van Damme P
DOI: 10.1007/s12032-017-1054-7
发表时间: 2017-11-07
期刊: Medical oncology (Northwood, London, England)
影响因子: --
作者:
Arechavaleta-Velasco F;Perez-Juarez CE;Gerton GL;Diaz-Cueto L
通讯作者: Diaz-Cueto L